BR0111937A - Ligantes crf2 em terapia combinada - Google Patents

Ligantes crf2 em terapia combinada

Info

Publication number
BR0111937A
BR0111937A BR0111937-0A BR0111937A BR0111937A BR 0111937 A BR0111937 A BR 0111937A BR 0111937 A BR0111937 A BR 0111937A BR 0111937 A BR0111937 A BR 0111937A
Authority
BR
Brazil
Prior art keywords
crf
crf2
ligands
antisense oligonucleotides
combination therapy
Prior art date
Application number
BR0111937-0A
Other languages
English (en)
Inventor
Siew Peng Ho
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of BR0111937A publication Critical patent/BR0111937A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"LIGANTES CRF~ 2~ EM TERAPIA COMBINADA". Esta invenção refere-se a oligonucleotídeos antisentido direcionados contra o mRNA do receptor subtipo-2 do fator de liberação de corticotropina (CRF~ 2~), que, reduz substancialmente, a expressão dos receptores de CRF~ 2~ no cérebro de roedores e ao uso dos oligonucleotídeo antisentido em testes do SNC in vivo de função genética e ao tratamento de uma ampla gama de distúrbios psiquiátricos, incluindo ansiedade, distúrbio obsessivo-compulsivo, distúrbios do pânico, distúrbio por estresse pós-traumático, fobias e depressão.
BR0111937-0A 2000-07-19 2001-07-19 Ligantes crf2 em terapia combinada BR0111937A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21939100P 2000-07-19 2000-07-19
PCT/US2001/022808 WO2002005749A2 (en) 2000-07-19 2001-07-19 Crf2 ligands in combination therapy

Publications (1)

Publication Number Publication Date
BR0111937A true BR0111937A (pt) 2005-04-12

Family

ID=22819077

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111937-0A BR0111937A (pt) 2000-07-19 2001-07-19 Ligantes crf2 em terapia combinada

Country Status (20)

Country Link
US (2) US20020035083A1 (pt)
EP (1) EP1383460A2 (pt)
JP (1) JP2004513880A (pt)
KR (1) KR20040014926A (pt)
CN (1) CN1501976A (pt)
AU (1) AU2001280632A1 (pt)
BG (1) BG107364A (pt)
BR (1) BR0111937A (pt)
CA (1) CA2416986A1 (pt)
CZ (1) CZ2003159A3 (pt)
EE (1) EE200300025A (pt)
HU (1) HUP0301833A3 (pt)
IL (1) IL153264A0 (pt)
IS (1) IS6673A (pt)
MX (1) MXPA02012721A (pt)
NO (1) NO20030214L (pt)
PL (1) PL365955A1 (pt)
RU (1) RU2003104509A (pt)
WO (1) WO2002005749A2 (pt)
ZA (1) ZA200300088B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073149A1 (en) * 2005-12-22 2007-06-28 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
JP2009528289A (ja) * 2006-02-27 2009-08-06 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
CA2692039C (en) 2007-06-13 2019-07-02 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
CN104231059B (zh) * 2013-06-19 2016-12-28 深圳翰宇药业股份有限公司 一种多肽及其制备方法和用途
MX2019004401A (es) 2016-10-20 2019-09-26 Cortene Inc Metodos de tratamiento y enfermedades resultantes de una respuesta de tension mal adaptada.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
EP0724637B2 (en) * 1994-06-14 2002-06-05 Neurocrine Biosciences, Inc. Corticotropin-releasing factor 2 receptors
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) * 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US6214797B1 (en) * 1995-06-13 2001-04-10 The Salk Institute For Biological Studies Urocortin peptides, nucleic acid encoding same methods for using same
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US5861398A (en) * 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
GB9717087D0 (en) * 1997-08-12 1997-10-15 Ciba Geigy Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
NO20030214D0 (no) 2003-01-16
PL365955A1 (en) 2005-01-24
IS6673A (is) 2003-01-08
BG107364A (bg) 2003-07-31
JP2004513880A (ja) 2004-05-13
HUP0301833A3 (en) 2005-12-28
IL153264A0 (en) 2003-07-06
WO2002005749A3 (en) 2003-11-06
AU2001280632A1 (en) 2002-01-30
MXPA02012721A (es) 2003-04-25
EE200300025A (et) 2005-04-15
RU2003104509A (ru) 2004-08-27
EP1383460A2 (en) 2004-01-28
CA2416986A1 (en) 2002-01-24
KR20040014926A (ko) 2004-02-18
US20020035083A1 (en) 2002-03-21
HUP0301833A2 (hu) 2003-09-29
ZA200300088B (en) 2005-05-09
NO20030214L (no) 2003-01-16
CN1501976A (zh) 2004-06-02
CZ2003159A3 (cs) 2004-02-18
WO2002005749A2 (en) 2002-01-24
US20050059627A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
MA26874A1 (fr) Arylpyrazines substituées
DK0639269T3 (da) Ionreservoir ved elektrodeoverflade
EP2324834A3 (en) Methods of Increasing Endogenous Erythropoietin (EPO)
BR9714820A (pt) Ligantes não-esteróides para o receptor de estrogênio
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
MXPA04004714A (es) Derivados de aril 1,4-pirazina sustituidos.
ATE506372T1 (de) Verfahren zur herstellung von nukleosidderivate
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
WO1998040055A3 (en) Anti-epileptogenic agents
DE59611341D1 (de) Verwendung von saccharid-konjugaten
NO994901D0 (no) Behandling av sentralnerveforstyrrelser ved selektive östrogenreseptormodulatorer
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
BR0111937A (pt) Ligantes crf2 em terapia combinada
WO2002085896A8 (en) Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
ATE254741T1 (de) Heizleitungsmatte und verfahren zum herstellen derselben
ES2162936T3 (es) Tratamiento de la ansiedad.
NO991542D0 (no) Anvendelse av svake stÕllegeringer for antikoksing
ATE334989T1 (de) Antidepressive azaheterocyclylmethyl-derivate von 2,3-dihydro-1,4-dioxino 2,3-föchinoxalin
DE60201592D1 (de) ANTIDEPRESSIVE INDOLTETRAHYDROPYRIDIN-DERIVATE VON 2,3-DIHYDRO-7H[1,4]DIOXINO[2,3-e]INDOL
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
DE69626860T2 (de) Elisa testsystem zur bestimmung von substanzen, die die bindung zwischen ig e und dessen receptor inhibiert
AU6363096A (en) Method for adsorbing antimicrobial agents contained in a bioogical fluid, and apparatus therefor
DE60325695D1 (de) Der eaat2-promotor und dessen verwendung
WO2000042178A3 (en) Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in in vivo cns studies of gene function

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.